SEARCH

SEARCH BY CITATION

References

  • 1
    Intensity Modulated Radiation Therapy Collaborative Working Group. Intensity-modulated radiotherapy: current status and issues of interest. Int J Radiat Oncol Biol Phys 2001; 51: 880914.
  • 2
    Barker JL, Jr., Garden AS, Ang KK, et al. Quantification of volumetric and geometric changes occurring during fractionated radiotherapy for head-and-neck cancer using an integrated CT/linear accelerator system. Int J Radiat Oncol Biol Phys 2004; 59: 960970.
  • 3
    Hansen E, Xia P, Quivey J, et al. The roles of repeat CT imaging and re-planning during the course of IMRT for patients with head and neck cancer. Paper presented at: ASTRO's 46th Annual Meeting; October 3–7, 2004; Atlanta, GA.
  • 4
    Pouliot J, Bani-Hashemi A, Chen J, et al. Low-dose megavoltage cone-beam CT for radiation therapy. Int J Radiat Oncol Biol Phys 2005; 61: 238241.
  • 5
    Pouliot J, Xia P, Langen K, et al. Dose-Guided Radiation Therapy using Low-Dose Megavoltage Cone-beam CT. in 44th Annual AAPM Annual Meeting. 2003. San Diego, CA: Med Phys.
  • 6
    Welsh JS, Patel RR, Ritter MA, et al. Helical tomotherapy: an innovative technology and approach to radiation therapy. Technol Cancer Res Treat 2002; 1: 311316.
  • 7
    Robinson JW, Moritz S, Fung T. Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. Int J Radiat Oncol Biol Phys 2002; 54: 10631068.
  • 8
    Litwin MS. Quality of life following definitive therapy for localized prostate cancer: potential impact of multiple therapies. Curr Opin Urol 2003; 13: 153156.
  • 9
    Talcott JA, Clark J, Stark P, et al. Long-term treatment-related complications of brachytherapy for early prostate cancer: A survey of treated patients. Proceedings of ASCO, 1999. 18: p. 311a.
  • 10
    Kupelian PA, Potters L, Khuntia D, et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy ≥72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 2004; 58: 2533.
  • 11
    Schellhammer PF, Moriarty R, Bostwick D, Kuban D. Fifteen-year minimum follow-up of a prostate brachytherapy series: comparing the past with the present. Urology 2000; 56: 436439.
  • 12
    Sylvester JE, Blasko JC, Grimm PD, et al. Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience. Int J Radiat Oncol Biol Phys 2003; 57: 944952.
  • 13
    Kuban DA, Thames HD, Levy LB, et al. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 2003; 57: 915928.
  • 14
    Moul JW, Connelly RR, Lubeck DP, et al. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases. J Urol 2001; 166: 13221327.
  • 15
    Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 15911597.
  • 16
    Michalski JM, Winter K, Purdy JA, et al. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV. Int J Radiat Oncol Biol Phys 2004; 58: 735742.
  • 17
    Michalski J, et al. Toxicity following 3D radiation therapy for prostate cancer on RTOG 9406 dose level V. Int J Radiat Oncol Biol Phys, 2003. 57 (2 Suppl): p. S151.
  • 18
    Ryu JK, Winter K, Michalski JM, et al. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). Int J Radiat Oncol Biol Phys 2002; 54: 10361046.
  • 19
    Dearnaley DP, Khoo VS, Norman AR, et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 1999; 353: 267272.
  • 20
    Nguyen LN, Pollack A, Zagars GK. Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire. Urology 1998; 51: 991997.
  • 21
    Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002; 53: 10971105.
  • 22
    Michalski JM, Winter K, Purdy JA, et al. Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II. Int J Radiat Oncol Biol Phys 2003; 56: 192198.
  • 23
    Roach M, Pickett B, Weil M, Verhey L. The “critical volume tolerance method” for estimating the limits of dose escalation during three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 1996; 35: 10191025.
  • 24
    Lee WR, Hanks GE, Hanlon AL, et al. Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: further evidence for a significant dose effect [see comments]. Int J Radiat Oncol Biol Phys 1996; 35: 251257.
  • 25
    Boyer AL, Butler EB, Dipetrillo TA, et al. Intensity-modulated radiotherapy: current status and issues of interest. Intensity Modulated Radiation Therapy Collaborative Working Group Int J Radiat Oncol Biol Phys 2001; 51: 880914.
  • 26
    Xia P, Pickett B, Vigneault E, et al. Forward or inversely planned segmental multileaf collimator IMRT and sequential tomotherapy to treat multiple dominant intraprostatic lesions of prostate cancer to 90 Gy. Int J Radiat Oncol Biol Phys 2001; 51: 244254.
  • 27
    Teh BS, Woo SY, Mai WY, et al. Clinical experience with intensity-modulated radiation therapy (IMRT) for prostate cancer with the use of rectal balloon for prostate immobilization. Med Dosim 2002; 27: 105113.
  • 28
    Shu HK, Lee TT, Vigneauly E, et al. Toxicity following high-dose three-dimensional conformal and intensity- modulated radiation therapy for clinically localized prostate cancer. Urology 2001; 57: 102107.
  • 29
    Teh BS, Woo SY, Woo, Butler EB. Intensity modulated radiation therapy (IMRT): a new promising technology in radiation oncology. Oncologist 1999; 4: 433442.
  • 30
    Zelefsky MJ, Fuks Z, Hunt M, et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 2002; 53: 11111116.
  • 31
    Langen KM, Jones DT. Organ motion and its management. Int J Radiat Oncol Biol Phys 2001; 50: 265278.
  • 32
    Roach M 3rd. Hormonal therapy and radiotherapy for localized prostate cancer: who, where and how long? J Urol 2003; 170: S35S40; discussion S40–S41.
  • 33
    Roach M, DeSilvio M, Thomas CR, Jr, et al. Progression Free Survival (PFS) after Whole-Pelvic (WP) vs “Mini-Pelvic” (MP) or Prostate Only (PO) Radiotherapy (RT): A Subset Analysis of RTOG 9413, a Phase III Prospective Randomized Trial Using Neoadjuvant and Concurrent (N&CHT) in Proceedings of the American Society for Therapeutic Radiology and Oncology. Atlanta, GA: Elsevier; 2004.
  • 34
    Jani AB, Blend MJ, Hamilton R, et al. Radioimmunoscintigraphy for postprostatectomy radiotherapy: analysis of toxicity and biochemical control. J Nucl Med 2004; 45: 13151322.
  • 35
    Schettino J, Kramer EL, Noz ME, et al. Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer. AJR Am J Roentgenol 2004; 183: 519524.
  • 36
    Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003; 348: 24912499.
  • 37
    Lee WR, Roach M 3rd, Michalski J, et al. Interobserver variability leads to significant differences in quantifiers of prostate implant adequacy. Int J Radiat Oncol Biol Phys 2002; 54: 457461.
  • 38
    Roach M 3rd, Faillace-Akazawa P, Malfatti C, et al. Prostate volumes defined by magnetic resonance imaging and computerized tomographic scans for three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 1996; 35: 10111018.
  • 39
    Kagawa K, Lee WR, Schultheiss TE, et al. Initial clinical assessment of CT-MRI image fusion software in localization of the prostate for 3D conformal radiation therapy. Int J Radiat Oncol Biol Phys 1997; 38: 319325.
  • 40
    Pickett B, Ten Haken RK, Kurhanewicz J, et al. Time to metabolic atrophy after permanent prostate seed implantation based on magnetic resonance spectroscopic imaging. Int J Radiat Oncol Biol Phys 2004; 59: 665673.
  • 41
    Roach M 3rd, Blasko JC, Perez CA, et al. Treatment planning for clinically localized prostate cancer. American College of Radiology. ACR Appropriateness Criteria. Radiology 2000; 215 (Suppl): 14411448.
  • 42
    Pouliot J, Aubin M, Langen KM, et al. (Non)-migration of radiopaque markers used for on-line localization of the prostate with an electronic portal imaging device. Int J Radiat Oncol Biol Phys 2003; 56: 862866.
  • 43
    Aubin M, Liu Y, Langen KM, et al. Set-up verification using portal images of implanted prostate markers: an interobserver study. Int J Radiat Oncol Biol Phys 2004; 54: S269S270.
  • 44
    Langen KM, Pouliot J, Anezinos C, et al. Evaluation of ultrasound-based prostate localization for image-guided radiotherapy. Int J Radiat Oncol Biol Phys 2003; 57: 635644.
  • 45
    Millender LE, Aubin M, Pouliot J, et al. Daily electronic portal imaging for morbidly obese men undergoing radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2004; 59: 610.
  • 46
    Fisch BM, Pickett B, Weinberg V, et al. Dose of radiation received by the bulb of the penis correlates with risk of impotence after three-dimensional conformal radiotherapy for prostate cancer. Urology 2001; 57: 955959.
  • 47
    Merrick GS, Butler WM, Wallner KE, et al. The importance of radiation doses to the penile bulb vs. crura in the development of postbrachytherapy erectile dysfunction. Int J Radiat Oncol Biol Phys 2002; 54: 10551062.
  • 48
    Merrick GS, Wallner K, Butler WM, et al. A comparison of radiation dose to the bulb of the penis in men with and without prostate brachytherapy-induced erectile dysfunction. Int J Radiat Oncol Biol Phys 2001; 50: 597604.
  • 49
    Roach M, Winter K, Michalski JM, et al. Penile Bulb Dose and Impotence Following 3D Conformal Radiotherapy For Prostate Cancer on RTOG 9406: Findings from a Prospective Multi-institutional Phase I-II Dose Escalation Study. Int J Radiat Oncol Biol Phys 2004; 60: 13511356.
  • 50
    Carrier S, Nagaraju P, Morgan DM, et al. Radiation-induced decrease in nitric oxide synthase-containing nerves in the rat penis. Radiology 1995; 195: 9599.
  • 51
    Weber DC, Bieri S, Kurtz JM, et al. Prospective pilot study of sildenafil for treatment of postradiotherapy erectile dysfunction in patients with prostate cancer. J Clin Oncol 1999; 17: 34443449.
  • 52
    Zelefsky MJ, McKee AB, Lee H, et al. Efficacy of oral sildenafil in patients with erectile dysfunction after radiotherapy for carcinoma of the prostate. Urology 1999; 53: 775778.
  • 53
    Buyyounouski MK, Horwitz EM, Uzzo RG, et al. The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy. Int J Radiat Oncol Biol Phys 2004; 59: 13831391.
  • 54
    Buyyounouski MK, Horwitz EM, Price RA, et al. Intensity-modulated radiotherapy with MRI simulation to reduce doses received by erectile tissue during prostate cancer treatment. Int J Radiat Oncol Biol Phys 2004; 58: 743749.
  • 55
    Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000; 48: 716.
  • 56
    Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med, 2003; 349: 20912098.
  • 57
    Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350: 19371944.
  • 58
    Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350: 19451952.
  • 59
    Bucci M, Xia P, Lee N, et al. Intensity modulated radiation therapy for carcinoma of the nasopharynx: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 2004; 60: S317S318.
  • 60
    Lee N, Xia P, Quivey JM, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 2002; 53: 1222.
  • 61
    Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998; 16: 13101317.
  • 62
    Chao KS, Deasy JO, Markman J, et al. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. Int J Radiat Oncol Biol Phys 2001; 49: 907916.
  • 63
    Lin A, Kim HM, Terrell JE, et al. Quality of life after parotid-sparing IMRT for head-and-neck cancer: a prospective longitudinal study. Int J Radiat Oncol Biol Phys 2003; 57: 6170.
  • 64
    Claus F, Boterberg T, Ost P, et al. Postoperative radiotherapy for adenocarcinoma of the ethmoid sinuses: treatment results for 47 patients. Int J Radiat Oncol Biol Phys 2002; 54: 10891094.
  • 65
    Claus F, Boterberg T, Ost P, et al. Short term toxicity profile for 32 sinonasal cancer patients treated with IMRT. Can we avoid dry eye syndrome? Radiother Oncol 2002; 64: 205208.
  • 66
    Withers HR. Biologic basis for altered fractionation schemes. Cancer 1985; 55: 20862095.
  • 67
    Thames HD, Jr, Withers HR, Peters LJ, et al. Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships. Int J Radiat Oncol Biol Phys 1982; 8: 219226.
  • 68
    Horiot JC, Bontemps P, van den Bogaert W, et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol 1997; 44: 111121.
  • 69
    Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999; 340: 265271.
  • 70
    Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991; 324: 16851690.
  • 71
    Lefebvre JL, Chevalier D, Luboinski B, et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996; 88: 890899.
  • 72
    Denis F, Garaud P, Bardet E, et al. Final results of the 94–01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004; 22: 6976.
  • 73
    Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999; 91: 20812086.
  • 74
    Garden AS, Wong MW, Tung P, et al. Preliminary results of intensity modulated radiation therapy for small primary oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2003; 57: S407.
  • 75
    Huang K, Lee N, Xia P, et al. Intensity-modulated radiotherapy in the treatment of oropharyngeal carcinoma: a single institutional experience. Int J Radiat Oncol Biol Phys 2003; 57: S302.
  • 76
    Peters LJ, Withers HR. Applying radiobio-logical principles to combined modality treatment of head and neck cancer–the time factor. Int J Radiat Oncol Biol Phys 1997; 39: 831836.
  • 77
    Taylor JM, Withers HR, Mendenhall WM. Dose-time considerations of head and neck squamous cell carcinomas treated with irradiation. Radiother Oncol 1990; 17: 95102.
  • 78
    Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988; 27: 131146.
  • 79
    Withers HR, Maciejewski B, Taylor JM, et al. Accelerated repopulation in head and neck cancer. Front Radiat Ther Oncol 1988; 22: 105110.
  • 80
    Bonner JA, Harari PM, Giralt J, et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: Phase III study of high dose radiation therapy with or without cetuximab. J Clin Oncol 2004; 22507.
  • 81
    Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 1030.
  • 82
    Tiwari RC, Ghosh K, Jemal A, et al. A new method of predicting US and state-level cancer mortality counts for the current calendar year. CA Cancer J Clin 2004; 54: 3040.
  • 83
    Bartelink H, Horiot JC, Poortmans P, et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 2001; 345: 13781387.
  • 84
    Romestaing P, Lehingue Y, Carrie C, et al. Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. J Clin Oncol 1997; 15: 963968.
  • 85
    Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 2004; 351: 971977.
  • 86
    Fyles AW, McCready DR, Manchul LA, et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med 2004; 351: 963970.
  • 87
    Fisher B, Bryant J, Dignam JJ, et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol 2002; 20: 41414149.
  • 88
    Athas WF, Adams-Cameron M, Hunt WC, et al. Travel distance to radiation therapy and receipt of radiotherapy following breast-conserving surgery. J Natl Cancer Inst 2000; 92: 269271.
  • 89
    Krueger EA, Fraass BA, Pierce LJ. Clinical aspects of intensity-modulated radiotherapy in the treatment of breast cancer. Semin Radiat Oncol 2002; 12: 250259.
  • 90
    Krueger EA, Fraass BA, McShan DL, et al. Potential gains for irradiation of chest wall and regional nodes with intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys 2003; 56: 10231037.
  • 91
    Li JS, Freedman GM, Price R, et al. Clinical implementation of intensity-modulated tangential beam irradiation for breast cancer. Med Phys 2004; 31: 10231031.
  • 92
    Whelan T, MacKenzie R, Julian J, et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst 2002; 94: 11431150.
  • 93
    Arthur DW, Vicini FA, Kuske RR, et al. Accelerated partial breast irradiation: an updated report from the American Brachytherapy Society. Brachytherapy 2002; 1: 184190.
  • 94
    Shah NM, Tenenholz T, Arthur D, et al. MammoSite and interstitial brachytherapy for accelerated partial breast irradiation: factors that affect toxicity and cosmesis. Cancer 2004; 101: 727734.
  • 95
    Keisch M, Vicini F, Kuske RR, et al. Initial clinical experience with the MammoSite breast brachytherapy applicator in women with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys 2003; 55: 289293.
  • 96
    Vaidya JS, Baum M, Tobias JS, et al. Targeted intra-operative radiotherapy (Targit): an innovative method of treatment for early breast cancer. Ann Oncol 2001; 12: 10751080.
  • 97
    Veronesi U, Orecchia R, Luini A, et al. A preliminary report of intraoperative radiotherapy (IORT) in limited-stage breast cancers that are conservatively treated. Eur J Cancer 2001; 37: 21782183.
  • 98
    Intra M, Gatti G, Luini A, et al. Surgical technique of intraoperative radiotherapy in conservative treatment of limited-stage breast cancer. Arch Surg 2002; 137: 737740.
  • 99
    Baglan KL, Sharpe MB, Jaffray D, et al. Accelerated partial breast irradiation using 3D conformal radiation therapy (3D-CRT). Int J Radiat Oncol Biol Phys 2003; 55: 302311.
  • 100
    Wallner P, Arthur D, Bartelink H, et al. Workshop on partial breast irradiation: state of the art and the science, Bethesda, MD, December 8–10, 2002. J Natl Cancer Inst 2004; 96: 175184.
  • 101
    Vaidya JS, Tobias JS, Baum M, et al. Intraoperative radiotherapy for breast cancer. Lancet Oncol 2004; 5: 165173.